Glucotrack, Inc. (GCTK): Entry into a Material Definitive Agreement
Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Glucotrack, Inc. Announces Pricing of $3 Million Public Offering RUTHERFORD, N.J. & LA JOLLA, Calif.: Sept. 24, 2026—(BUSINESS WIRE)—Glucotrack, Inc. (NASDAQ: GCTK) (“Glucotrack” or the “Company”) today announced the pricing of a “best efforts” public offering of 169
How this was made
The 30-second read
Why it matters
The capital raise is intended to fund ongoing development of its investigational device and corporate operations.
Market read
A small‑scale equity raise for a micro‑cap biotech; limited immediate market impact.
What to watch
Potential strategic partnership with Lōkahi Therapeutics could add long‑term value beyond the immediate cash.
Background
Glucotrack is a Nasdaq‑listed biotech focused on continuous glucose monitoring technology.
Ticker impact
Glucotrack announced pricing of a $3.1M public offering of common stock and pre‑funded warrants.
Potential slight downward pressure on GCTK as new shares are issued.
Small raise size relative to market cap suggests limited market impact, but dilution risk may affect price.
Market effects
Minor signal for the diabetes‑monitoring device sector; no broad sector shift.
Limited to US micro‑cap investors.
Low
Counterpoint
The modest raise may be a sign of cash constraints, suggesting caution.
Key entities
- companyGlucotrack, Inc.
Issuer of the public offering.
- placement_agentDawson James Securities, Inc.
Sole placement agent for the offering.
